Note | Tousled-like kinase 2 (TLK2), together with Tousled-like kinase 1 ( TLK1), belongs to Tousled-like kinases family of serine/threonine kinases (Silljé et al., 1999; Mortuza et al., 2018; Segura-Bayona and Stracker, 2019). As a cell cycle regulated enzyme, TLK2 exhibits its highest level of activity during S-phase (Silljé et al., 1999). TLK2 is composed of an N-Terminal region harboring a nuclear localization signal (NLS), a middle region of helixes containing three putative coiled coil (CC) domains and a C-terminal protein kinase catalytic domain. The C-terminal region of the protein kinase domain is known to carry multiple potential phosphorylation sites in its carboxy-terminus (C-tail) (Groth et al., 2003; Krause et al., 2003; Klimovskaia et al., 2014; Mortuza et al., 2018). TLK2 is activated through cis-autophosphorylation events in its kinase domain. These autophosphorylation events induce a conformational change which allows further phosphorylation in the C-tail of TLK2 (Mortuza et al., 2018). The monomeric TLK2 exhibits a negligible catalytic activity in comparison to its dimeric form (Mortuza et al., 2018; Segura-Bayona and Stracker, 2019). Homodimerization of TLK2 or heterodimerization with TLK1 requires the presence of the first coiled coil (CC1) domain. Activated/phosphorylated dimers of TLK2 can display higher orders of oligomerization through further phosphorylation of the phosphor-sites in the loops joining the CC domains (Mortuza et al., 2018). This oligomerization can trigger activation and may also increase the enzymatic activity through recruiting additional TLK2 molecules. While the dimeric/oligomeric constructs of TLK2 are able to phosphorylate a specific substrate, ASF1A, the kinase domain alone do not display this property, suggesting that either the CC domains or their role in oligomerization is crucial for substrate recognition (Mortuza et al., 2018; Segura-Bayona and Stracker, 2019). Mechanism and role of other phosphorylations at the N terminus remain to be further investigated (Hornbeck et al., 2015; Segura-Bayona and Stracker, 2019). |
| |
|  |
| |
| Figure 3. The longest isoform of TLK2 is encoded by 772 amino acids and consists of a regulatory domain and a kinase domain. Regulatory domain contains NLS region and coiled coil domains. Kinase domain has an ATP binding region and a catalytic loop. |
| |
Description | TLK2 longest transcript encodes for 772 amino acids. Molecular weight is 87,661 Da. |
Expression | TLK2 transcript is mostly expressed in testis but also in brain, eye, endocrine tissues, lung, proximal digestive tract, gastrointestinal tract, liver and gallbladder, pancreas, kidney, urinary bladder, female tissues, muscle tissues, adipose and soft tissue, skin, bone marrow, lymphoid tissues and blood. (https://www.proteinatlas.org/ENSG00000146872-TLK2/tissue). |
Localisation | TLK2 is a nuclear protein but its subcellular localization may change depending on the cell cycle. TLK2 colocalizes to cytoplasmic intermediate filaments during G1 phase and to the perinuclear region at S phase (Yamakawa et.al., 1997; Zhang et.al., 1999). |
Function | Cell Cycle and DNA Damage Following its identification as a mammalian homologue of A. thaliana Tousled kinase, TLK2 has been linked to a wide-range of cellular functions (Sillje et al., 1999). TLK2 exhibits a constitutive expression pattern throughout the cell cycle whereas its kinase activity fluctuates during the cell cycle and peaking in the S-phase (Sillje et al., 1999). Inhibition of DNA-replication and induction of DNA-damage in mid-S phase cells with various agents (e.g. aphidicolin, hydroxyurea, cisplatin, bleomycin, topoisomerase inhibitors, ionizing radiation) substantially decrease TLK2 kinase activity (Sillje et al., 1999; Groth et al., 2003). These results suggest that there is a direct link between TLK2 activity and ongoing DNA-replication and this activity is inhibited as a result of stalled replication fork on damaged DNA. In support, TLK2 activity is associated with maintenance of replication fork integrity and chromatin assembly (Lee et al., 2018). siRNA-mediated knockdown of TLK2 reduces the rate of DNA replication fork progression, disrupt replication-coupled nucleosome assembly and result in accumulation of replication-dependent single-stranded DNA. Moreover, sustained depletion of TLK2 result in accumulation of replication-dependent DNA-damage which in turn cause a TP53 -mediated G1-S checkpoint arrest (Lee et al., 2018). However, how TLK2 promotes genome stability and its role in DNA damage response (DDR) remain to be fully elucidated. One possible mechanism to associate TLK2 activity with DDR is based on the fact that H3/H4 histone chaperone ASF1 is an interacting partner of TLKs (Sillje and Nigg, 2001). TLK-mediated phosphorylation of ASF1 positively regulates ASF1a protein levels, hinders its proteasomal degradation (Pilyugin et al., 2009) and stimulates its association with soluble histones and downstream chaperones, CAF-1 and HIRA (Klimovskaia et al., 2014). In yeast, ASF1 is implicated in maintenance of genome stability and checkpoint recovery through its direct interaction with CHEK2 (RAD53) (Emili et al., 2001; Hu et al., 2001), but in mammalian cells it is indirectly regulated by checkpoint kinases through activities of TLKs (Segura-Bayona and Stracker, 2019). Although a direct interaction of Checkpoint kinase 1 ( CHEK1) with TLK2 has not been demonstrated in proteomics studies (Segura-Bayona et al., 2017), its paralog TLK1 has been reported as a substrate of CHEK1. Phosphorylation of TLK1 at serine 695 (S695) in response to DNA-damage results in transient inhibition of TLK1 activity (Groth et al., 2003; Krause et al., 2003). This modulation of TLK1 activity by CHEK1 may be a key event for regulating histone binding capacity of ASF1 and to allow chromatin restoration during DNA-repair. Interestingly, overexpression of TLK2 in T47D cells disrupt the CHEK1/2-mediated DDR signaling, resulting in a delayed DNA repair process, impaired G2/M checkpoint and an enhanced chromosome instability (Kim et al., 2016a). However, it has not yet been fully elucidated whether TLK2 is also directly regulated by CHEK1 or by heterodimerization with C-terminally phosphorylated TLK1 (Segura-Bayona and Stracker, 2019). On the other hand, TLK2 controls chromatin restoration after DNA-damage during G2 arrest through histone chaperone ASF1A. In the absence of TLK2, improper chromatin restoration results in decreases expression of pro-mitotic genes such as; CCNB1 (Cyclin B1) and PLK1 which in turn compromised cellular competence to recover from cell cycle arrests induced by DNA-damage (Bruinsma et al., 2016). The Drosophila genome includes a single Tousled-like kinase gene and the encoded Tlk plays dual function to prolong the G2-phase and to promote the G2 recovery via modulating the "p38a" (symbol provided by Flybase for Drosophila genes) activity. According to the proposed model, Tlk remains in an inactive form when its cellular level is low. Alternatively, Tlk kinase activity can be inactivated as a consequence of dATM/DCHEK1 activity triggered by a stress-induced DNA and/or histone damage. This inactive Tlk associates with "Tak1", "Hsc70-5" (Flybase) and EEF1A1. The resulting protein complex elevates p38a activity, which in turn causes a delay in G2 phase. On the other hand, under conditions where TLK activity is high, active Tlk promotes G2 recovery by decreasing p38a activity and increasing ASF1 activity (Liaw and Chian, 2019). Cancer TLK2 function has been linked to patient outcomes in a variety of human cancers including breast cancer, glioblastoma, uveal melanoma, cervical squamous cell carcinoma and endocervical adenocarcinoma (Kim et al., 2016b; Lin et al., 2018; Lee et al., 2018). Analysis of copy number, RNA-seq and survival data sets for breast tumors from The Cancer Genome Atlas Project (TCGA) showed that TLK2 is amplified in nearly 10% of ER-positive breast cancers and its resulting overexpression correlates with worse clinical outcome (Kim et al., 2016b). A phosphoproteomic analyses of TCGA breast cancer samples performed by The Clinical Proteomic Tumor Analysis Consortium (CPTAC) independently identified TLK2 as an amplicon-associated, highly phosphorylated kinase in luminal breast cancers (Mertins et al., 2016). Ectopic expression of TLK2 in T47D luminal breast cancer cell line, which normally possesses low TLK2 levels, results in increased invasion and cell migration and this aggressiveness reversed upon withdrawal of TLK2 expression (Kim et al., 2016b). The TLK2 overexpression-mediated invasiveness of breast cancer cells may be attributed to EGFR / SRC / PTK2 (FAK) signaling axis as TLK2 overexpression increases phosphorylation of EGFR, SRC and FAK. Conversely, siRNA-mediated knockdown of SRC, FAK or EGFR decreased the migration ability of TLK2-overexpressing T47D cells (Kim et al., 2016b). shRNA targeting of TLK2 suppresses ESR1 (ERα), BCL2 and SKP2 protein levels, upregulates CDKN1B (p27), impairs cell cycle progression through G1/S border, decreases colony-forming ability, induces apoptosis and significantly improves progression-free survival in vivo (Kim et al., 2016b). Activation of SRC signaling axis by TLK2 and effects of this relation on cancer progression was also proved by studies performed with glioblastoma cells (Lin et al., 2018). TLK2 is upregulated in invasive glioblastoma samples in comparison to normal tissues and non-invasive glioblastoma samples, and this upregulation is associated with worse patient outcomes. Overexpression of TLK2 in glioblastoma cells increased cell growth, invasion and migration, while silencing TLK2 result in cell cycle arrest at G2/M checkpoint and ultimately induction of apoptosis. Expression analysis for markers of epithelial-to-mesenchymal transition indicated that TLK2 overexpression is associated with decreased levels of epithelial markers CDH1 (E-cadherin) and TJP1 (ZO-1), whereas mesenchymal marker vimentin is increased. On the other hand, TLK2 knockdown resulted in an opposite effect (Lin et al., 2018). In vivo analysis of TLK2 activity on cancer progression created a link between TLK2 knockdown and reduction in tumor growth and metastasis (Lin et al., 2018). Development In addition to its roles in replication, cell cycle regulation and maintenance of genome stability TLK2 function also implicated in mammalian development. The characterization studies performed with TLK2-defficient mice suggested that TLK2 is required for normal differentiation of trophoblast lineages. TLK2 deficiency in mice resulted in late embryonic lethality due to placental failure. Histological examination of the labyrinths of TLK2 deficient mice placenta indicate a disorganized structure composed of less mature and less differentiated trophoblasts. Taken together, these data suggest a requirement to TLK2 for proper placental development and function (Segura-Bayona et al., 2017). This effect of TLK2 may be a consequence of its roles in transcriptional regulation (Bruinsma et al., 2016). TLK2 loss was also correlated with decreased histone chaperon ASF1 (Anti-Silencing Function 1) phosphorylation (Segura-Bayona et al., 2017). |
Homology | TLK2 is conserved among species such as chimpanzee, Rhesus monkey, dog, cow, mouse, rat, chicken, zebrafish, fruit fly, C. elegans and frog (https://www.ncbi.nlm.nih.gov/). |
Identification of differentially expressed genes associated with osteochondrosis in standardbred horses using RNA arbitrarily primed PCR |
Austbø L, Røed KH, Dolvik NI, Skretting G |
Anim Biotechnol 2010 Apr;21(2):135-9. |
PMID 20379890 |
|
Tousled-like kinase 2 regulates recovery from a DNA damage-induced G2 arrest |
Bruinsma W, van den Berg J, Aprelia M, Medema RH |
EMBO Rep 2016 May;17(5):659-70. |
PMID 26931568 |
|
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data |
Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N |
Cancer Discov 2012 May;2(5):401-4. |
PMID 22588877 |
|
Gene profiling involved in immature CD4+ T lymphocyte responsible for systemic lupus erythematosus |
Deng YJ, Huang ZX, Zhou CJ, Wang JW, You Y, Song ZQ, Xiang MM, Zhong BY, Hao F |
Mol Immunol 2006 Mar;43(9):1497-507. |
PMID 16143398 |
|
Dynamic interaction of DNA damage checkpoint protein Rad53 with chromatin assembly factor Asf1 |
Emili A, Schieltz DM, Yates JR, Hartwell LH |
Mol Cell 2001 Jan;7(1):13-20. |
PMID 11172707 |
|
Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal |
Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N |
Sci Signal 2013 Apr 2;6(269):pl1. |
PMID 23550210 |
|
A Cross-Study Biomarker Signature of Human Bronchial Epithelial Cells Infected with Respiratory Syncytial Virus |
Gardinassi LG |
Adv Virol 2016;2016:3605302. |
PMID 27274726 |
|
Human Tousled like kinases are targeted by an ATM- and Chk1-dependent DNA damage checkpoint |
Groth A, Lukas J, Nigg EA, Silljé HH, Wernstedt C, Bartek J, Hansen K |
EMBO J 2003 Apr 1;22(7):1676-87. |
PMID 12660173 |
|
Spatial and temporal mapping of de novo mutations in schizophrenia to a fetal prefrontal cortical network |
Gulsuner S, Walsh T, Watts AC, Lee MK, Thornton AM, Casadei S, Rippey C, Shahin H, , , Nimgaonkar VL, Go RC, Savage RM, Swerdlow NR, Gur RE, Braff DL, King MC, McClellan JM |
Cell 2013 Aug 1;154(3):518-29. |
PMID 23911319 |
|
PhosphoSitePlus, 2014: mutations, PTMs and recalibrations |
Hornbeck PV, Zhang B, Murray B, Kornhauser JM, Latham V, Skrzypek E |
Nucleic Acids Res 2015 Jan;43(Database issue):D512-20. |
PMID 25514926 |
|
Asf1 links Rad53 to control of chromatin assembly |
Hu F, Alcasabas AA, Elledge SJ |
Genes Dev 2001 May 1;15(9):1061-6. |
PMID 11331602 |
|
Genetic variation in the chromosome 17q23 amplicon and breast cancer risk |
Kelemen LE, Wang X, Fredericksen ZS, Pankratz VS, Pharoah PD, Ahmed S, Dunning AM, Easton DF, Vierkant RA, Cerhan JR, Goode EL, Olson JE, Couch FJ |
Cancer Epidemiol Biomarkers Prev 2009 Jun;18(6):1864-8. |
PMID 19454617 |
|
Amplification of TLK2 Induces Genomic Instability via Impairing the G2-M Checkpoint |
Kim JA, Anurag M, Veeraraghavan J, Schiff R, Li K, Wang XS |
Mol Cancer Res 2016 Oct;14(10):920-927. |
PMID 27489360 |
|
Comprehensive functional analysis of the tousled-like kinase 2 frequently amplified in aggressive luminal breast cancers |
Kim JA, Tan Y, Wang X, Cao X, Veeraraghavan J, Liang Y, Edwards DP, Huang S, Pan X, Li K, Schiff R, Wang XS |
Nat Commun 2016 Oct 3;7:12991. |
PMID 27694828 |
|
Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan |
Kim ST, Ahn TJ, Lee E, Do IG, Lee SJ, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim SH, Lee J, Kim HC |
BMC Cancer 2015 Oct 20;15:747. |
PMID 26486455 |
|
Tousled-like kinases phosphorylate Asf1 to promote histone supply during DNA replication |
Klimovskaia IM, Young C, Strømme CB, Menard P, Jasencakova Z, Mejlvang J, Ask K, Ploug M, Nielsen ML, Jensen ON, Groth A |
Nat Commun 2014 Mar 6;5:3394. |
PMID 24598821 |
|
Suppression of Tousled-like kinase activity after DNA damage or replication block requires ATM, NBS1 and Chk1 |
Krause DR, Jonnalagadda JC, Gatei MH, Sillje HH, Zhou BB, Nigg EA, Khanna K |
Oncogene 2003 Sep 4;22(38):5927-37. |
PMID 12955071 |
|
GSVD comparison of patient-matched normal and tumor aCGH profiles reveals global copy-number alterations predicting glioblastoma multiforme survival |
Lee CH, Alpert BO, Sankaranarayanan P, Alter O |
PLoS One 2012;7(1):e30098. |
PMID 22291905 |
|
Tousled-like kinases stabilize replication forks and show synthetic lethality with checkpoint and PARP inhibitors |
Lee SB, Segura-Bayona S, Villamor-Payà M, Saredi G, Todd MAM, Attolini CS, Chang TY, Stracker TH, Groth A |
Sci Adv 2018 Aug 8;4(8):eaat4985. |
PMID 30101194 |
|
Meta-analysis of 2,104 trios provides support for 10 new genes for intellectual disability |
Lelieveld SH, Reijnders MR, Pfundt R, Yntema HG, Kamsteeg EJ, de Vries P, de Vries BB, Willemsen MH, Kleefstra T, Löhner K, Vreeburg M, Stevens SJ, van der Burgt I, Bongers EM, Stegmann AP, Rump P, Rinne T, Nelen MR, Veltman JA, Vissers LE, Brunner HG, Gilissen C |
Nat Neurosci 2016 Sep;19(9):1194-6. |
PMID 27479843 |
|
Inactive Tlk associating with Tak1 increases p38 MAPK activity to prolong the G2 phase |
Liaw GJ, Chiang CS |
Sci Rep 2019 Feb 13;9(1):1885. |
PMID 30760733 |
|
TLK2 enhances aggressive phenotypes of glioblastoma cells through the activation of SRC signaling pathway |
Lin M, Yao Z, Zhao N, Zhang C |
Cancer Biol Ther 2019;20(1):101-108. |
PMID 30207834 |
|
Proteogenomics connects somatic mutations to signalling in breast cancer |
Mertins P, Mani DR, Ruggles KV, Gillette MA, Clauser KR, Wang P, Wang X, Qiao JW, Cao S, Petralia F, Kawaler E, Mundt F, Krug K, Tu Z, Lei JT, Gatza ML, Wilkerson M, Perou CM, Yellapantula V, Huang KL, Lin C, McLellan MD, Yan P, Davies SR, Townsend RR, Skates SJ, Wang J, Zhang B, Kinsinger CR, Mesri M, Rodriguez H, Ding L, Paulovich AG, Fenyö D, Ellis MJ, Carr SA, |
Nature 2016 Jun 2;534(7605):55-62. |
PMID 27251275 |
|
Molecular basis of Tousled-Like Kinase 2 activation |
Mortuza GB, Hermida D, Pedersen AK, Segura-Bayona S, López-Méndez B, Redondo P, Rüther P, Pozdnyakova I, Garrote AM, Muñoz IG, Villamor-Payà M, Jauset C, Olsen JV, Stracker TH, Montoya G |
Nat Commun 2018 Jun 28;9(1):2535. |
PMID 29955062 |
|
Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations |
O', Roak BJ, Deriziotis P, Lee C, Vives L, Schwartz JJ, Girirajan S, Karakoc E, Mackenzie AP, Ng SB, Baker C, Rieder MJ, Nickerson DA, Bernier R, Fisher SE, Shendure J, Eichler EE |
Nat Genet 2011 Jun;43(6):585-9. |
PMID 21572417 |
|
Phosphorylation-mediated control of histone chaperone ASF1 levels by Tousled-like kinases |
Pilyugin M, Demmers J, Verrijzer CP, Karch F, Moshkin YM |
PLoS One 2009 Dec 16;4(12):e8328. |
PMID 20016786 |
|
De Novo and Inherited Loss-of-Function Variants in TLK2: Clinical and Genotype-Phenotype Evaluation of a Distinct Neurodevelopmental Disorder |
Reijnders MRF, Miller KA, Alvi M, Goos JAC, Lees MM, de Burca A, Henderson A, Kraus A, Mikat B, de Vries BBA, Isidor B, Kerr B, Marcelis C, Schluth-Bolard C, Deshpande C, Ruivenkamp CAL, Wieczorek D, , Baralle D, Blair EM, Engels H, Lüdecke HJ, Eason J, Santen GWE, Clayton-Smith J, Chandler K, Tatton-Brown K, Payne K, Helbig K, Radtke K, Nugent KM, Cremer K, Strom TM, Bird LM, Sinnema M, Bitner-Glindzicz M, van Dooren MF, Alders M, Koopmans M, Brick L, Kozenko M, Harline ML, Klaassens M, Steinraths M, Cooper NS, Edery P, Yap P, Terhal PA, van der Spek PJ, Lakeman P, Taylor RL, Littlejohn RO, Pfundt R, Mercimek-Andrews S, Stegmann APA, Kant SG, McLean S, Joss S, Swagemakers SMA, Douzgou S, Wall SA, Küry S, Calpena E, Koelling N, McGowan SJ, Twigg SRF, Mathijssen IMJ, Nellaker C, Brunner HG, Wilkie AOM |
Am J Hum Genet 2018 Jun 7;102(6):1195-1203. |
PMID 29861108 |
|
Whole genome paired-end sequencing elucidates functional and phenotypic consequences of balanced chromosomal rearrangement in patients with developmental disorders |
Schluth-Bolard C, Diguet F, Chatron N, Rollat-Farnier PA, Bardel C, Afenjar A, Amblard F, Amiel J, Blesson S, Callier P, Capri Y, Collignon P, Cordier MP, Coubes C, Demeer B, Chaussenot A, Demurger F, Devillard F, Doco-Fenzy M, Dupont C, Dupont JM, Dupuis-Girod S, Faivre L, Gilbert-Dussardier B, Guerrot AM, Houlier M, Isidor B, Jaillard S, Joly-Hélas G, Kremer V, Lacombe D, Le Caignec C, Lebbar A, Lebrun M, Lesca G, Lespinasse J, Levy J, Malan V, Mathieu-Dramard M, Masson J, Masurel-Paulet A, Mignot C, Missirian C, Morice-Picard F, Moutton S, Nadeau G, Pebrel-Richard C, Odent S, Paquis-Flucklinger V, Pasquier L, Philip N, Plutino M, Pons L, Portnoï MF, Prieur F, Puechberty J, Putoux A, Rio M, Rooryck-Thambo C, Rossi M, Sarret C, Satre V, Siffroi JP, Till M, Touraine R, Toutain A, Toutain J, Valence S, Verloes A, Whalen S, Edery P, Tabet AC, Sanlaville D |
J Med Genet 2019 Aug;56(8):526-535. |
PMID 30923172 |
|
Differential requirements for Tousled-like kinases 1 and 2 in mammalian development |
Segura-Bayona S, Knobel PA, González-Burón H, Youssef SA, Peña-Blanco A, Coyaud , López-Rovira T, Rein K, Palenzuela L, Colombelli J, Forrow S, Raught B, Groth A, de Bruin A, Stracker TH |
Cell Death Differ 2017 Nov;24(11):1872-1885. |
PMID 28708136 |
|
Identification of human Asf1 chromatin assembly factors as substrates of Tousled-like kinases |
Silljé HH, Nigg EA |
Curr Biol 2001 Jul 10;11(13):1068-73. |
PMID 11470414 |
|
Evaluation of associations between common variation in mitotic regulatory pathways and risk of overall and high grade breast cancer |
Stevens KN, Wang X, Fredericksen Z, Pankratz VS, Cerhan J, Vachon CM, Olson JE, Couch FJ |
Breast Cancer Res Treat 2011 Sep;129(2):617-22. |
PMID 21607584 |
|
Abeta42 generation is toxic to endothelial cells and inhibits eNOS function through an Akt/GSK-3beta signaling-dependent mechanism |
Suhara T, Magrané J, Rosen K, Christensen R, Kim HS, Zheng B, McPhie DL, Walsh K, Querfurth H |
Neurobiol Aging May-Jun 2003;24(3):437-51. |
PMID 12600720 |
|
Severe neurodevelopmental disease caused by a homozygous TLK2 variant |
Töpf A, Oktay Y, Balaraju S, Yilmaz E, Sonmezler E, Yis U, Laurie S, Thompson R, Roos A, MacArthur DG, Yaramis A, Güngör S, Lochmüller H, Hiz S, Horvath R |
Eur J Hum Genet 2020 Mar;28(3):383-387. |
PMID 31558842 |
|
Integrative Analyses of De Novo Mutations Provide Deeper Biological Insights into Autism Spectrum Disorder |
Takata A, Miyake N, Tsurusaki Y, Fukai R, Miyatake S, Koshimizu E, Kushima I, Okada T, Morikawa M, Uno Y, Ishizuka K, Nakamura K, Tsujii M, Yoshikawa T, Toyota T, Okamoto N, Hiraki Y, Hashimoto R, Yasuda Y, Saitoh S, Ohashi K, Sakai Y, Ohga S, Hara T, Kato M, Nakamura K, Ito A, Seiwa C, Shirahata E, Osaka H, Matsumoto A, Takeshita S, Tohyama J, Saikusa T, Matsuishi T, Nakamura T, Tsuboi T, Kato T, Suzuki T, Saitsu H, Nakashima M, Mizuguchi T, Tanaka F, Mori N, Ozaki N, Matsumoto N |
Cell Rep 2018 Jan 16;22(3):734-747. |
PMID 29346770 |
|
Genetic regulatory network analysis for app based on genetical genomics approach |
Wang X, Chen Y, Wang X, Lu L |
Exp Aging Res Jan-Mar 2010;36(1):79-93. |
PMID 20054728 |
|
cDNA cloning and chromosomal mapping of genes encoding novel protein kinases termed PKU-alpha and PKU-beta, which have nuclear localization signal |
Yamakawa A, Kameoka Y, Hashimoto K, Yoshitake Y, Nishikawa K, Tanihara K, Date T |
Gene 1997 Nov 20;202(1-2):193-201. |
PMID 9427565 |
|
Nuclear localization of protein kinase U-alpha is regulated by 14-3-3 |
Zhang S, Xing H, Muslin AJ |
J Biol Chem 1999 Aug 27;274(35):24865-72. |
PMID 10455159 |
|